DuoBody-CD3xCD20

DuoBody®-CD3xCD20 is a proprietary bispecific antibody created using Genmab’s DuoBody technology. It targets CD20, a clinical well-validated target. In a number of laboratory models, this DuoBody has shown unusually high potency in killing CD20+ tumors. It is further differentiated from other CD20 antibodies due to an optimized formulation designed to effectively reduce peak cytokine levels. DuoBody-CD3xCD20 has potential in multiple B-cell malignancies. During the fourth quarter of 2017 both an IND and a CTA were filed for DuoBody-CD3xCD3 with a Phase I/II study is planned to start in 2018.

Back to top

DuoBody-CD3xCD20 has potential in multiple B-cell malignancies. A Phase I/II study is planned to start in 2018.

Back to top